NBRV News and Press, Nabriva Therapeutics plc From 09/10/20

Nabriva Therapeutics ( NBRV +6.7% )   announces that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for Xenleta (lefamulin) for injection when administered in the hospital inpatient setting. More news on: Nabriva Therapeut...

-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship -CONTEPO first Qualified Infectious Disease Product to receive NTAP conditional approval prior to FDA approval DUBLIN, Ireland, Sept. 10, 2020 (GLOBE NE...

DUBLIN, Ireland, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will participate in two u...

Nabriva Therapeutics Plc (NBRV) Q2 2020 Earnings Conference Call August 6, 2020 16:30 ET Company Participants Gary Sender - Chief Financial Officer Ted Schroeder - Chief Executive Officer Francesco Maria Lavino - Chief Commercial Officer Jennifer Schranz - Chief Medical Officer...

The following slide deck was published by Nabriva Therapeutics plc in conjunction with their 2020 Q2 earnings Read more ...

Nabriva Therapeutics (NASDAQ: NBRV ) : Q2 GAAP EPS of -$0.30 misses by $0.15 . More news on: Nabriva Therapeutics plc, Earnings news and commentary, Healthcare stocks news, , Read more ...

-SIVEXTRO ® adds revenue generating product creating additional scale and synergies- -Relaunch of XENLETA ® and SIVEXTRO planned with targeted in-person promotion- -Conference call today at 4:30 p.m. Eastern Time- DUBLIN, Ireland, Aug. 06, 2020 (GLOBE NEWSWIRE) -- ...

DUBLIN, Ireland, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter fi...

DUBLIN, Ireland, July 30, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer...

- XENLETA represents the first new antibiotic class approved for patients with CAP in Europe in nearly 20 years -XENLETA approval provides urgently needed short-course, empiric monotherapy treatment option for CAP aligned with core principles of antimicrobial stewardship DUBLIN, J...